Overcoming Peanut Allergies: Oral Immunotherapy

Authored by: Max Turtz

Art by: Kain Wang

Growing up with a peanut allergy profoundly shaped my life long before I understood science. At three years old, after my mother ate a peanut butter cookie and kissed me, I broke out in hives. From that moment on, vigilance became routine. I sat at a separate allergen-free table in elementary school, read every food label for cross-contamination, and carried an EpiPen in case of accidental exposure. Annual skin and blood tests initially showed persistently high sensitivity levels. However, by middle school, my levels began to decline, and I eventually began oral immunotherapy (OIT), consuming tiny but increasing doses of peanut powder mixed into chocolate pudding under hospital supervision. Over the course of a year, I reached a maintenance dose of eating eight peanuts a day indefinitely. After two years at this level, I passed a challenge where I consumed three times my maintenance dose with no reaction, effectively ending my allergy. This personal journey illustrates the transformative potential of OIT for individuals with peanut allergies and highlights the importance of research to guide its safe implementation. 

Peanut allergies affect approximately 1–2% of children in the United States and are a leading cause of food-induced anaphylaxis, contributing to significant anxiety and public health burden [1]. Reactions can range from mild symptoms, such as hives, to life-threatening systemic responses that require immediate epinephrine administration, such as anaphylactic shock that causes immense breathing difficulty [2]. Historically, allergy management has relied on avoidance of peanut-containing foods and readiness to respond to accidental exposures. While this approach can prevent harm, it places a substantial and ongoing burden on patients and their families. Avoidance is complicated not only by high-risk environments like schools, but also by broader challenges such as inconsistent food labeling, cross-contamination during food preparation, and limited public understanding of allergy severity. Dining out, traveling, and navigating social situations further increase uncertainty, as individuals often have little control over ingredients or preparation methods. Together, these factors make strict avoidance difficult to sustain and contribute to significant stress. 

Oral immunotherapy has emerged as a promising intervention to increase tolerance to peanut protein through gradual, medically supervised exposure [3]. Randomized, controlled trials indicate that OIT can significantly increase the threshold of peanut protein tolerated by patients, thereby reducing the risk of severe reactions after accidental ingestion [2]. Evidence further suggests that children undergoing OIT experience improved quality of life, with greater confidence in consuming potentially cross-contaminated foods and participating in social activities [4]. 

Despite its promises, OIT carries risks. Adverse events, including gastrointestinal symptoms and systemic allergic reactions, are more frequent in OIT-treated patients than in controls, occasionally requiring epinephrine administration [5]. Long-term safety remains an area of active investigation, as do optimal dosing protocols and strategies to maintain adherence over time. Additionally, accessibility challenges exist. OIT is primarily offered in specialized clinics, with geographic and economic barriers limiting widespread availability. Disparities in access may prevent some populations from benefiting from this potentially life-changing intervention [2, 3]. 

Emerging research explores strategies to mitigate these limitations. Adjunct therapies, which combine with OIT, have shown promise in reducing adverse events and accelerating desensitization [3]. Early initiation in childhood also appears to increase the likelihood of sustained tolerance, highlighting the importance of timely intervention [6]. Additionally, efforts to train primary care providers in administering OIT protocols aim to broaden access and reduce disparities [5]. 

In conclusion, oral immunotherapy represents a transformative approach to managing peanut allergies, offering the potential to improve both safety and quality of life. While my personal experience demonstrates the freedom and confidence OIT can provide, research is essential to define its efficacy, long-term safety, and accessibility. Continued investigation will guide evidence-based protocols, improve patient outcomes, and ultimately expand the reach of OIT to children and families affected by peanut allergies. 

References

1. Sicherer, S. H., & Sampson, H. A. (2018). Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. Journal of Allergy and Clinical Immunology, 141(1), 41–58. https://doi.org/10.1016/j.jaci.2017.11.003  

2. Khan, N. A., et al. (2025). Efficacy and Safety of Oral Immunotherapy for Peanut Allergy: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials. International archives of allergy and immunology, 1–14. Advance online publication. https://doi.org/10.1159/000548282   

3. Tian, X., Liu, S., Li, L. et al (2025). Comparative Efficacy of Combined and Standalone Oral Immunotherapies for Peanut Allergy: a Bayesian Network Meta-Analysis of RCTs. Clinic Rev Allerg Immunol 68, 113. https://doi.org/10.1007/s12016-025-09118-2  

4. Mahase, E. (2022). Peanut allergy: One in five children achieved lasting remission after oral immunotherapy, study reports. BMJ, 376, o164. https://doi.org/10.1136/bmj.o164  

5. Landry, V., Lewis, R., Lewis, W. et al. (2024). Safety and adherence of early oral immunotherapy for peanut allergy in a primary care setting: A retrospective cross-sectional study. Allergy Asthma Clin Immunol 20, 57. https://doi.org/10.1186/s13223-024-00916-5

6.  National Institutes of Health (NIH). (2022). Oral immunotherapy induces remission of peanut allergy in some young children. NIH. https://www.niaid.nih.gov/news-events/oral-immunotherapy-induces-remission-peanut-allergy-some-young-children